PharmNovo starts clinical phase I studies for its lead candidate for treatmemt of neuropathic pain.


The drug candidate PN6047 from PharmNovo is an entirely new drug. The substance is a selective delta opioid, a so-called DORA (delta opioid receptor agonist), which, in animal models, effectively relieves nerve pain. It does so without causing the unwanted side effects of conventional opioid drugs on the market today.

During the summer, the application to start clinical studies of PN6047 was approved by the Swedish Medical Products Agency and Ethical Review Authority. Last Monday, the first dose was given to humans.

Read the full Press release

Follow us: